IONS240719P42500
- 0.35
- 0.000.00%
Ionis Pharmaceuticals Newsroom
Unusual Options Activity: MRVL, IONS and Others Attract Market Bets, MRVL V/OI Ratio Reaches 375.0
EST Jul 25th Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Shareholders Might Be Looking For Exit
Express News | Ionis Pharmaceuticals Shares up 1.3% Premarket After Leerink Partners Raises to Outperform From Market Perform
Express News | Ionis Pharmaceuticals Inc : Leerink Partners Raises Target Price to $62 From $53
Express News | Ionis Pharmaceuticals Inc : Leerink Partners Raises to Outperform From Market Perform
Leerink Partners Upgrades Ionis Pharmaceuticals to Outperform, Raises Price Target to $62
Leerink Partners Upgrades Ionis Pharmaceuticals(IONS.US) to Buy Rating, Announces Target Price $62
Leerink Partners analyst Mani Foroohar upgrades $Ionis Pharmaceuticals(IONS.US)$ to a buy rating, and sets the target price at $62.According to TipRanks data, the analyst has a success rate of 39.7%
Ionis Pharmaceuticals' ION582: Promising Angelman Syndrome Drug Faces Clinical and Commercial Uncertainties
Ionis Pharmaceuticals Is Maintained at Buy by B of A Securities
B of A Securities Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $68
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $48 to $82
On Jul 23, major Wall Street analysts update their ratings for $Ionis Pharmaceuticals(IONS.US)$, with price targets ranging from $48 to $82.Morgan Stanley analyst Michael Ulz maintains with a hold
Express News | Ionis Pharmaceuticals Inc : TD Cowen Raises Target Price to $59 From $54
TD Cowen Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)
Express News | Ionis Pharmaceuticals Inc : BofA Global Research Raises Price Objective to $68 From $67
Buy Rating on Ionis Pharmaceuticals Backed by Strong Trial Results for Angelman Syndrome Drug
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Lifestance Health Group (LFST) and Agilent (A)
Ionis Pharmaceuticals' ION582 Garners Buy Rating Amidst Promising Efficacy and Safety Data
Express News | Ionis Pharmaceuticals Inc : Jefferies Raises Target Price to $77 From $75
Health Care Stocks Post Moderate Gains -- Health Care Roundup
Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target